These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 33139260)

  • 1. Does my healthy 65-year-old patient still need the 13-valent pneumococcal conjugate vaccine (PCV13)?
    Nielsen CD; Jin XW
    Cleve Clin J Med; 2020 Nov; 87(11):656-658. PubMed ID: 33139260
    [No Abstract]   [Full Text] [Related]  

  • 2. Immunogenicity and safety of a booster dose of the 13-valent pneumococcal conjugate vaccine in children primed with the 10-valent or 13-valent pneumococcal conjugate vaccine in the Czech Republic and Slovakia.
    Urbancikova I; Prymula R; Goldblatt D; Roalfe L; Prymulova K; Kosina P
    Vaccine; 2017 Sep; 35(38):5186-5193. PubMed ID: 28797727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Nuorti JP; Whitney CG;
    MMWR Recomm Rep; 2010 Dec; 59(RR-11):1-18. PubMed ID: 21150868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Invasive Pneumococcal Disease in Infants Aged 0-60 Days in the United States in the 13-Valent Pneumococcal Conjugate Vaccine Era.
    Olarte L; Barson WJ; Bradley JS; Tan TQ; Lin PL; Romero JR; Givner LB; Hoffman JA; Hultén KG; Mason EO; Kaplan SL
    J Pediatric Infect Dis Soc; 2018 Aug; 7(3):249-252. PubMed ID: 28510699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of 13-valent pneumococcal conjugate vaccine for prevention of invasive pneumococcal disease in children in the USA: a matched case-control study.
    Moore MR; Link-Gelles R; Schaffner W; Lynfield R; Holtzman C; Harrison LH; Zansky SM; Rosen JB; Reingold A; Scherzinger K; Thomas A; Guevara RE; Motala T; Eason J; Barnes M; Petit S; Farley MM; McGee L; Jorgensen JH; Whitney CG
    Lancet Respir Med; 2016 May; 4(5):399-406. PubMed ID: 26987984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent Updates to the Advisory Committee On Immunization Practices Recommendations for Pneumococcal and Herpes Zoster Vaccination.
    Brotherton AL; Shah R
    R I Med J (2013); 2020 Aug; 103(6):34-37. PubMed ID: 32752563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of administering 13-valent pneumococcal conjugate vaccine in addition to 23-valent pneumococcal polysaccharide vaccine to adults with immunocompromising conditions.
    Cho BH; Stoecker C; Link-Gelles R; Moore MR
    Vaccine; 2013 Dec; 31(50):6011-21. PubMed ID: 24148572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Uptake of 13-Valent Pneumococcal Conjugate Vaccine among US Adults Aged 19 to 64 Years with Immunocompromising Conditions.
    Vietri J; Harnett J; Emir B; Chilson E
    Hum Vaccin Immunother; 2020; 16(1):161-168. PubMed ID: 31343949
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naïve adults ≥50 years of age.
    Ermlich SJ; Andrews CP; Folkerth S; Rupp R; Greenberg D; McFetridge RD; Hartzel J; Marchese RD; Stek JE; Abeygunawardana C; Musey LK
    Vaccine; 2018 Oct; 36(45):6875-6882. PubMed ID: 29559167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of vaccinating the elderly and at-risk adults with the 23-valent pneumococcal polysaccharide vaccine or 13-valent pneumococcal conjugate vaccine in the UK.
    Jiang Y; Gauthier A; Keeping S; Carroll S
    Expert Rev Pharmacoecon Outcomes Res; 2014 Dec; 14(6):913-27. PubMed ID: 25189087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Persistence of antibodies 1 year after sequential administration of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine in adults.
    Schmoele-Thoma B; van Cleeff M; Greenberg RN; Gurtman A; Jones TR; Sundaraiyer V; Gruber WC; Scott DA
    Hum Vaccin Immunother; 2019; 15(3):575-583. PubMed ID: 30648932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary Care Physicians' Struggle with Current Adult Pneumococcal Vaccine Recommendations.
    Hurley LP; Allison MA; Pilishvili T; O'Leary ST; Crane LA; Brtnikova M; Beaty BL; Lindley MC; Bridges CB; Kempe A
    J Am Board Fam Med; 2018; 31(1):94-104. PubMed ID: 29330244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recommendations for the prevention of Streptococcus pneumoniae infections in infants and children: use of 13-valent pneumococcal conjugate vaccine (PCV13) and pneumococcal polysaccharide vaccine (PPSV23).
    American Academy of Pediatrics Committee on Infectious Diseases
    Pediatrics; 2010 Jul; 126(1):186-90. PubMed ID: 20498180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults.
    Jackson LA; Gurtman A; van Cleeff M; Jansen KU; Jayawardene D; Devlin C; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
    Vaccine; 2013 Aug; 31(35):3577-84. PubMed ID: 23688526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children - Advisory Committee on Immunization Practices (ACIP), 2010.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2010 Mar; 59(9):258-61. PubMed ID: 20224542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The cost-effectiveness of pneumococcal vaccination in healthy adults over 50: An exploration of influential factors for Belgium.
    Blommaert A; Bilcke J; Willem L; Verhaegen J; Goossens H; Beutels P
    Vaccine; 2016 Apr; 34(18):2106-12. PubMed ID: 26988257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥65 Years: Updated Recommendations of the Advisory Committee on Immunization Practices.
    Matanock A; Lee G; Gierke R; Kobayashi M; Leidner A; Pilishvili T
    MMWR Morb Mortal Wkly Rep; 2019 Nov; 68(46):1069-1075. PubMed ID: 31751323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Invasive pneumococcal disease and 13-valent pneumococcal conjugate vaccine (PCV13) coverage among children aged ≤59 months---selected U.S. regions, 2010--2011.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2011 Nov; 60(43):1477-81. PubMed ID: 22048728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccine Failures in Patients Properly Vaccinated with 13-Valent Pneumococcal Conjugate Vaccine in Catalonia, a Region with Low Vaccination Coverage.
    Moraga-Llop F; Garcia-Garcia JJ; Díaz-Conradi A; Ciruela P; Martínez-Osorio J; González-Peris S; Hernández S; de Sevilla MF; Uriona S; Izquierdo C; Selva L; Campins M; Codina G; Batalla J; Esteva C; Domínguez À; Muñoz-Almagro C
    Pediatr Infect Dis J; 2016 Apr; 35(4):460-3. PubMed ID: 26658626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naïve adults 60-64 years of age.
    Greenberg RN; Gurtman A; Frenck RW; Strout C; Jansen KU; Trammel J; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
    Vaccine; 2014 Apr; 32(20):2364-74. PubMed ID: 24606865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.